ArticleGland surgery2026
Pleomorphic adenoma as a clinicopathological continuum: borderline/atypical lesions, surgical control, and malignant transformation in a 1,306-case cohort.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pleomorphic adenoma (PA) of the salivary gland, particularly of the parotid gland, is generally considered benign but exhibits heterogeneous biological behavior, including recurrence and malignant transformation. While benign pleomorphic adenoma (BPA) and carcinoma ex pleomorphic adenoma (CXPA) are well defined, lesions with borderline or atypical features represent a clinically challenging gray zone with unclear surgical implications. This study aimed to characterize the clinicopathological features of borderline/atypical PA (BaPA) within the PA spectrum and to evaluate its recurrence parttern and malignant transformation risk. Methods: We conducted a single-center retrospective cohort study of surgically treated PAs diagnosed between 2008 and 2023. Cases were categorized as BPA, BaPA, and CXPA based on standardized histopathological re-review. BaPA and CXPA were considered higher-risk lesions within the PA spectrum. Preoperative fine-needle aspiration (FNA) concordance, Ki-67 proliferation index, surgical approach, and recurrence were analyzed, with follow-up focused on pathology-confirmed recurrence. Results: A total of 1,306 cases were included, of which 87.9% arose in the parotid gland. FNA concordance with final diagnosis was high in BPA (84.0%) but substantially lower in BaPA (54.4%) and CXPA (32.1%). Ki-67 increased stepwise across tumor categories and showed good discriminative ability for malignant transformation (area under the curve =0.841), with an optimal cutoff value of 10%. During follow-up, recurrence occurred in 15.5% of BaPA and 27.0% of CXPA cases. In BaPA, recurrence was associated with surgical approach; in sensitivity analysis excluding enucleation cases, recurrence remained significantly lower after total parotidectomy than after superficial parotidectomy (7.0% Conclusions: These findings support PA as a clinicopathological continuum and suggest that BaPA may represent an intermediate-risk subgroup within this spectrum. Adequate local surgical control, awareness of the limitations of FNA, and incorporation of Ki-67 (≥10%) may aid individualized risk stratification and postoperative surveillance, while further validation of this category is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.